114 related articles for article (PubMed ID: 38441231)
1. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract][Full Text] [Related]
2. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
Bill MA; Fuchs JR; Li C; Yui J; Bakan C; Benson DM; Schwartz EB; Abdelhamid D; Lin J; Hoyt DG; Fossey SL; Young GS; Carson WE; Li PK; Lesinski GB
Mol Cancer; 2010 Jun; 9():165. PubMed ID: 20576164
[TBL] [Abstract][Full Text] [Related]
3. STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses.
Jahangiri A; Dadmanesh M; Ghorban K
J Cell Physiol; 2020 Dec; 235(12):9457-9463. PubMed ID: 32401358
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
5. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Fossey SL; Bear MD; Lin J; Li C; Schwartz EB; Li PK; Fuchs JR; Fenger J; Kisseberth WC; London CA
BMC Cancer; 2011 Mar; 11():112. PubMed ID: 21443800
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
[TBL] [Abstract][Full Text] [Related]
7. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
8. The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.
Lai HW; Chien SY; Kuo SJ; Tseng LM; Lin HY; Chi CW; Chen DR
Evid Based Complement Alternat Med; 2012; 2012():486568. PubMed ID: 21876713
[TBL] [Abstract][Full Text] [Related]
9. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
11. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Lin L; Deangelis S; Foust E; Fuchs J; Li C; Li PK; Schwartz EB; Lesinski GB; Benson D; Lü J; Hoyt D; Lin J
Mol Cancer; 2010 Aug; 9():217. PubMed ID: 20712901
[TBL] [Abstract][Full Text] [Related]
13. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
Pero SC; Shukla GS; Cookson MM; Flemer S; Krag DN
Br J Cancer; 2007 May; 96(10):1520-5. PubMed ID: 17426702
[TBL] [Abstract][Full Text] [Related]
15. Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.
Wu X; Tang W; Marquez RT; Li K; Highfill CA; He F; Lian J; Lin J; Fuchs JR; Ji M; Li L; Xu L
Oncotarget; 2016 Mar; 7(10):11708-23. PubMed ID: 26887043
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
Front Immunol; 2021; 12():654749. PubMed ID: 33936081
[TBL] [Abstract][Full Text] [Related]
17. Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions.
Grubczak K; Kretowska-Grunwald A; Groth D; Poplawska I; Eljaszewicz A; Bolkun L; Starosz A; Holl JM; Mysliwiec M; Kruszewska J; Wojtukiewicz MZ; Moniuszko M
Cells; 2021 Aug; 10(8):. PubMed ID: 34440813
[TBL] [Abstract][Full Text] [Related]
18. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
19. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
20. Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia.
Zhang J; Dewilde AH; Chinn P; Foreman A; Barry S; Kanne D; Braunhut SJ
Int J Hyperthermia; 2011; 27(7):682-97. PubMed ID: 21992561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
